Company
Insightec
Last checked: Nov 20, 2026Source: SEC EDGAR, openFDA and ClinicalTrials.govMethods & limitations
FDA decisions since 2015
6
510(k), De Novo and PMA
Device trials
81
As lead sponsor, any status
Adverse event reports
27
Received Nov 1, 2025 to Nov 20, 2026
Recall records
0
One per recalled product
This company is not on our public-company list, so only this exact name is matched. Naming a company here is not a recommendation of it or of any security.
Financing
Not publicly listed. It has raised money in private placements reported to the SEC on Form D (filings through 2026Q3). A company with no recent filing may since have been acquired.
Total raised (reported)
$436M
3 Form D offerings, 2017 to 2024
Equity
$436M
Stock sold for cash
Debt and convertible notes
$0
Loans and notes sold to investors
Last known valuation
Unknown
Form D filings do not report valuation
Latest round: equity, $150M raised of $150M sought, first sale Jun 17, 2024, 39 investors.
Funding rounds (Form D)
One row per Form D offering, newest first. The amount raised is the latest amended figure. An offering can run for months and close in several tranches. Matched by company name, so check the filing.
| First sale | Type | Raised | Round size | Investors | Exemption and agent | Filing |
|---|---|---|---|---|---|---|
| Jun 17, 2024 | Equity | $150M | $150M | 39 | Rule 506(b) | Form D ↗Jun 28, 2024 |
| Mar 18, 2020 | Equity | $136M | $150M | 16 | Rule 506(b) | Form D/A ↗Apr 7, 20212 amendments |
| Dec 27, 2017 | Equity | $150M | $150M | 242 non-accredited | Rule 506(b)Agent: Marc Belzberg, Exigent Management Ltd. | Form D ↗Feb 14, 2018 |
Company details
From the company's latest Form D.
- Legal name
- INSIGHTEC LTD
- Headquarters
- Tirat Carmel, Israel
- Incorporated
- Israel over five years before filing
- Entity type
- Private Limited Company
- Revenue range
- Decline to Disclose
- Industry filed under
- Other Health Care
- SEC filer
- CIK 1376126 ↗
Executives, directors and promoters
As listed on the latest Form D.
15 more people on the filing with a free account
Not in public filings: valuations, share prices and investors' names. Private databases such as PitchBook and Crunchbase estimate these from press releases and surveys. Not every round is filed: companies raising under other exemptions, or from foreign investors only, may not file Form D. Nothing here is investment advice.
Investors
5%+ shareholders from SEC Schedule 13D/13G filings since Dec 1, 2024, and SBIR/STTR grants (NIH through Nov 10, 2026, other agencies through 2023). Venture investors in private rounds are not in public filings.
No 5%+ shareholder filings or SBIR grants found under the name Insightec.
Latest FDA decisions
- Exablate Model 4000 Type-1 SystemPMA supplement
P150038-S037 · Decided Jul 3, 2025 · 352 days after receipt · Panel Track
Device type: MR-guided focused ultrasound system (POH) · Neurology & Neurosurgery
K231378 · Decided Oct 30, 2023 · 171 days after receipt
Device type: High Intensity Ultrasound System For Prostate Tissue Ablation (PLP) · GI, Urology & Nephrology
- Exablate Prostate System510(k)
K212150 · Decided Nov 23, 2021 · 137 days after receipt
Device type: High Intensity Ultrasound System For Prostate Tissue Ablation (PLP) · GI, Urology & Nephrology
3 more FDA decisions with a free account
Device trials
Trials on ClinicalTrials.gov that list this company as lead sponsor, most recently updated first.
- Unilateral and Staged Bilateral Pallidothalamic Tractotomy Using Exablate MRgFUS in Advanced Parkinson's Disease.Pivotal-lookingNot yet recruiting
NCT07764874 · 120 participants (planned) · Start Nov 2026 · Primary completion Dec 2029
Device: Unilateral Exablate MRgFUS Pallidothalamic Tractotomy; Staged Bilateral Exablate Pallidothalamic Tractotomy · For: Parkinson Disease
Sites: Seoul, South Korea
- MR-guided Focused Ultrasound Plus GCaseActive, not recruiting
NCT05565443 · 14 participants (planned) · Start Nov 30, 2022 · Primary completion Nov 1, 2026
Device: Blood Brain Barrier Disruption - Functional · For: Parkinsons Disease
Sites: Toronto, Canada
- MRI-Guided Focused Ultrasound Feasibility Study for Brain TumorsActive, not recruiting
NCT00147056 · 10 participants (planned) · Start Aug 2012 · Primary completion Dec 2026
Device: ExAblate transcranial system · For: Brain Tumor
Sites: Boston, Massachusetts; Seattle, Washington
78 more trials with a free account
Reports received
27
Received Nov 1, 2025 to Nov 20, 2026
Malfunction reports
0
0.0% of reports
Injury reports
27
100% of reports
Death reports
0
0.0% of reports
Adverse event reports received per month
Reports that name this company as manufacturer, by the date FDA received them. The newest month is incomplete.
- Malfunction
- Injury
- Death
- Other
View as table
| Month | Malfunction | Injury | Death | Other |
|---|---|---|---|---|
| Dec 23 | 0 | 2 | 0 | 0 |
| Jan 24 | 0 | 1 | 0 | 0 |
| Feb 24 | 0 | 6 | 0 | 0 |
| Mar 24 | 0 | 3 | 0 | 0 |
| Apr 24 | 0 | 4 | 0 | 0 |
| May 24 | 0 | 8 | 0 | 0 |
| Jun 24 | 0 | 3 | 0 | 0 |
| Jul 24 | 0 | 2 | 0 | 0 |
| Aug 24 | 0 | 1 | 0 | 0 |
| Sep 24 | 0 | 1 | 0 | 0 |
| Oct 24 | 0 | 2 | 0 | 0 |
| Nov 24 | 0 | 1 | 0 | 0 |
| Dec 24 | 0 | 4 | 0 | 0 |
| Jan 25 | 0 | 0 | 0 | 0 |
| Feb 25 | 0 | 4 | 0 | 0 |
| Mar 25 | 0 | 6 | 0 | 0 |
| Apr 25 | 0 | 2 | 0 | 0 |
| May 25 | 0 | 19 | 0 | 0 |
| Jun 25 | 0 | 1 | 0 | 0 |
| Jul 25 | 0 | 4 | 0 | 0 |
| Aug 25 | 0 | 2 | 0 | 0 |
| Sep 25 | 0 | 0 | 0 | 0 |
| Oct 25 | 0 | 2 | 0 | 0 |
| Nov 25 | 0 | 3 | 0 | 0 |
| Dec 25 | 0 | 1 | 0 | 0 |
| Jan 26 | 0 | 1 | 0 | 0 |
| Feb 26 | 0 | 0 | 0 | 0 |
| Mar 26 | 0 | 4 | 0 | 0 |
| Apr 26 | 0 | 2 | 0 | 0 |
| May 26 | 0 | 7 | 0 | 0 |
| Jun 26 | 0 | 6 | 0 | 0 |
| Jul 26 | 0 | 1 | 0 | 0 |
| Aug 26 | 0 | 1 | 0 | 0 |
| Sep 26 | 0 | 0 | 0 | 0 |
| Oct 26 | 0 | 1 | 0 | 0 |
| Nov 26 | 0 | 0 | 0 | 0 |
Device types named most often
Last 12 months, by FDA product code. A company that sells more gets more reports.
Brand names named most often
Last 12 months, as written on the reports. One product can appear under several spellings.
Recent recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recalls under this name in FDA's data.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.